In ACH, the glycine-to-arginine mutation at position 380 (G380R) is harbored by 99% of the patients, affecting the transmembrane domain of FGFR3 [45], which activates FGFR3 signaling [46]. This evidence concerns the gene FGFR3 and achondroplasia.